文献速递毛发、甲与色素性疾病

造血干细胞移植后新发白癜风:韩国全国性人群队列研究

Subsequent vitiligo after hematopoietic stem cell transplantation: A nationwide population-based cohort study from Korea.
PubMed 文献 · J Am Acad Dermatol · 2016-11-08

该研究基于韩国全国健康保险理赔数据库(2009–2013年),纳入2010–2011年接受造血干细胞移植(HSCT)且2009年未治疗白癜风的2747例受者,并设年龄性别匹配的8241例对照。结果显示HSCT受者新发白癜风发生率为1.06%,显著高于对照组的0.34%(OR 3.130,95%CI 1.859-5.271)。异基因HSCT(OR 5.593,95%CI 1.628-19.213)和骨髓来源干细胞(相较于外周血来源,OR 2.492,95%CI 1.114-5.576)是独立危险因素。

要点

  • HSCT后新发白癜风发生率1.06%,显著高于对照的0.34%(OR 3.130)。
  • 异基因HSCT与白癜风风险独立相关(OR 5.593)。
  • 骨髓来源干细胞较外周血来源风险更高(OR 2.492)。

核心结论

  • HSCT受者新发白癜风发生率显著高于无HSCT对照。
  • 异基因HSCT和骨髓来源干细胞是HSCT后白癜风的独立危险因素。

研究设计与样本

  • 全国性、人群为基础队列研究,使用韩国国家健康保险理赔数据库2009–2013年数据。
  • 纳入2010–2011年接受HSCT且2009年未治疗白癜风的2747例受者,并设年龄性别匹配的8241例无HSCT对照。

主要发现

  • HSCT受者2010–2013年间新发白癜风发生率为1.06%,对照组为0.34%。
  • HSCT受者白癜风风险显著增加(OR 3.130,95%CI 1.859-5.271)。
  • 异基因HSCT与白癜风风险独立相关(OR 5.593,95%CI 1.628-19.213)。
  • 骨髓来源干细胞较外周血来源干细胞风险更高(OR 2.492,95%CI 1.114-5.576)。

临床怎么用

  • HSCT后患者应关注白癜风新发可能,尤其异基因移植和骨髓来源干细胞受者。

局限性

  • 无法进行病历回顾。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Subsequent vitiligo after hematopoietic stem cell transplantation (HSCT) has been described sporadically in case series. OBJECTIVE: To investigate the incidence and risk factors of subsequent vitiligo after HSCT. METHODS: A nationwide, population-based cohort study was performed using the Korean National Health Insurance Claims Database from 2009 to 2013. All HSCT recipients who had undergone HSCT between 2010 and 2011 and not treatment for vitiligo in 2009 (to exclude preexisting active vitiligo) were included in the HSCT recipient group, and an age- and sex-matched control group without HSCT was also established. RESULTS: A total of 2747 HSCT recipients and 8241 controls were enrolled. Newly acquired vitiligo occurred in 1.06% of HSCT recipients between 2010 and 2013, and there was a significant increase (OR 3.130, 95% CI 1.859-5.271) in cases of vitiligo in HSCT recipients compared with controls (0.34%). Allogeneic HSCT (OR 5.593, 95% CI 1.628-19.213) and bone marrow-sourced stem cells (as compared with peripheral blood-sourced stem cells; OR 2.492, 95% CI 1.114-5.576) were independently associated with the development of vitiligo after HSCT. LIMITATIONS: Medical record review was not available. CONCLUSION: Vitiligo developed at a significantly increased rate after HSCT compared with controls. Allogeneic HSCT and bone marrow-sourced stem cells were independent risk factors.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Bae JM, Choi KH, Jung HM, et al. Subsequent vitiligo after hematopoietic stem cell transplantation: A nationwide population-based cohort study from Korea. J Am Acad Dermatol. 2016. PMID: 27836331. doi:10.1016/j.jaad.2016.08.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。